Q
Quang T. Luong
Researcher at Cedars-Sinai Medical Center
Publications - 4
Citations - 209
Quang T. Luong is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Vitamin D and neurology & Retinoid X receptor. The author has an hindex of 4, co-authored 4 publications receiving 197 citations. Previous affiliations of Quang T. Luong include University of Birmingham.
Papers
More filters
Journal ArticleDOI
Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.
Claudia I. Muller,Claudia I. Muller,Carl W. Miller,Wolf-K. Hofmann,Mitchell E. Gross,Christine Walsh,Norihiko Kawamata,Quang T. Luong,Quang T. Luong,H. Phillip Koeffler +9 more
TL;DR: No PIK3CA mutations were found in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and non-Hodgkin lymphomas (NHL) as well as in osteosarcomas, prostate and ovarian cancer samples, and a previously unidentified Pik3CA pseudogene spanning exons 9-13 on chromosome 22 was discovered.
Journal Article
Vitamin D Compounds: Activity Against Microbes and Cancer
TL;DR: The anticancer and newly discovered antimicrobial actions of 1,25(OH)2D3 and deltanoids are reviewed.
Journal ArticleDOI
Vitamin D compounds in leukemia.
TL;DR: Pre-clinical studies suggest that the combination of either 1,25(OH)(2)D3 or its analogs with other agents can have additive or synergistic anti-cancer activities, suggesting future clinical studies.
Journal ArticleDOI
Identification of marker genes including RUNX3 (AML2) that discriminate between different myeloproliferative neoplasms and normal individuals.
Claudia I. Muller,Claudia I. Muller,Quang T. Luong,Quang T. Luong,Shih Ly,Letetia C. Jones,Julian C. Desmond,Norihiko Kawamata,O. Tcherniantchouk,Qiang Liu,Kosei Ito,Kosei Ito,Motomi Osato,Motomi Osato,Yoshiaki Ito,Yoshiaki Ito,Ayalew Tefferi,S. de Vos,H P Koeffler +18 more
TL;DR: Identification of marker genes including RUNX3 ( AML2) that discriminate between different myeloproliferative neoplasms and normal individuals is confirmed.